Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.

Blood Adv · 2025 · PMC12008683 · PMID 39820359

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We measured numerically lower CD8 + and CD4 + JCAR021 Cmax compared to JCAR014 at either dose level, although this did not reach statistical significance ( supplemental Table 11 ), and comparable transgene persistence ( supplemental Figure 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.